Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection

Journal of Glaucoma

Volumn 16, Issue 2, 2007, Pages 251-256

  Iwao, Keiichiro ^a   Inatani, Masaru ^a   Kawaji, Takahiro ^a   Koga, Takahisa ^a   Mawatari, Yuki ^a   Tanihara, Hidenobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Corticosteroid; Glaucoma; Trabeculotomy

Indexed keywords

ANTIGLAUCOMA AGENT; LEVOFLOXACIN; OFLOXACIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LENS CAPSULE; MAJOR CLINICAL STUDY; MALE; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; RISK FACTOR; SURGICAL INFECTION; TRABECULECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONNECTIVE TISSUE; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; TRIAMCINOLONE ACETONIDE;

EID: 34247629681     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31802d696f     Document Type: Article

References (47)

1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
2. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
3. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-224. Discussion 224-225.
4. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044-2049.
5. Jonas JB, Akkoyun I, Kreissig I, et al. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol. 2005;89:321-326.
6. Tewari HK, Sony P, Chawla R, et al. Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders. Eur J Ophthalmol. 2005;15:619-626.
7. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2005;19:65-71.
8. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
9. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004;122:218-222.
10. Jonas JB, Spandau UH, Harder B, et al. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 2005;139:1073-1079.
11. Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2-6.
12. Androudi S, Letko E, Meniconi M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005;13:205-212.
13. Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol. 2003;121:271-273.
14. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol. 2003;121:1663-1664.
15. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
16. Deckers V, Priem H, Verbraeken H. One year of intravitreal injections of steroids. Bull Soc Belge Ophtalmol. 2005;297:69-77.
17. Koga T, Mawatari Y, Inumaru J, et al. Trans-Tenon's retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2005;243:1247-1252.
18. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, et al. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol. 1999;237:289-295.
19. Okada AA, Wakabayashi T, Morimura Y, et al. Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol. 2003;87:968-971.
20. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 2005;139:290-294.
21. Verma LK, Vivek MB, Kumar A, et al. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther. 2004;20:277-284.
22. Helm CJ, Holland GN. The effect of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120:55-64.
23. Levin DS, Han DP, Dev S, et al. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Am J Ophthalmol. 2002;133:196-202.
24. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol. 1987;103:281-288.
25. Nozik RA. Periocular injection of steroids. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:695-705.
26. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-743.
27. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmol. 2005; 112:593-598.
28. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol. 1999;27:431-432.
29. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336-340.
30. Ripart J, Metge L, Prat-Pradal D, et al. Medial canthus single-injection episcleral (sub-tenon anesthesia): computed tomography imaging. Anesth Analg. 1998;87:42-45.
31. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114.
32. Kwok AK, Lam DS, Ng JS, et al. Ocular-hypertensive response to topical steroids in children. Ophthalmology. 1997;104:2112-2116.
33. Becker B, Bresnick G, Chevrette L, et al. Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol. 1966;76:477-483.
34. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the advanced glaucoma intervention study. Ophthalmol. 2004;111:1627-1635.
35. Bengtsson B, Heijl A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma. 2005;14:135-138.
36. Morgan CM, Schatz H, Vine AK, et al. Ocular complications associated with retrobulbar injections. Ophthalmology. 1988;95:660-665.
37. Moshfeghi DM, Lowder CY, Roth DB, et al. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol. 2002;134:132-134.
38. Engelman CJ, Palmer JD, Egbert P. Orbital abscess following subtenon triamcinolone injection. Arch Ophthalmol. 2004;122:654-655.
39. Gallardo MJ, Johnson DA. Cutaneous hypopigmentation following a posterior sub-tenon triamcinolone injection. Am J Ophthalmol. 2004;137:779-780.
40. Dal Canto AJ, Downs-Kelly E, Perry JD. Ptosis and orbital fat prolapse after posterior sub-Tenon's capsule triamcinolone injection. Ophthalmol. 2005;112:1092-1097.
41. Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol. 2003;121:729-730.
42. Honjo M, Tanihara H, Inatani M, et al. External trabeculotomy for the treatment of steroid-induced glaucoma. J Glaucoma. 2000;9:483-485.
43. Yun AJ, Murphy CG, Polansky JR, et al. Proteins secreted by human trabecular cells. Glucocorticoid and other effects. Invest Ophthalmol Vis Sci. 1989;30:2012-2022.
44. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci. 1990;31:2568-2571.
45. Steely HT, Browder SL, Julian MB, et al. The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1992;33:2242-2250.
46. Dickerson JE Jr, Steely HT Jr, English-Wright SL, et al. The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells. Exp Eye Res. 1998;66:731-738.
47. Clark AF, Steely HT, Dickerson JE Jr, et al. Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci. 2001;42:1769-1780.